Climb Bio, Inc. (CLYM) stock forecast and price target
Price $10.36 · data as of November 13, 2026
12-month price target
Average target$28.40
Upside / downside+174.1%
Analysts15
ConsensusStrong buy
Low $18.00Average $28.40High $40.00
Gold marker: average target · white marker: today’s price ($10.36)
Analyst ratings
Strong buy 2Buy 14Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.75 | +14.8% | $0 |
| Next fiscal year ends December 31, 2027 | $-0.99 | −32.5% | $500000 |
| Next quarter ends December 31, 2026 | $-0.19 | +26.1% | $0 |
| Quarter after ends March 31, 2027 | $-0.23 | −13.0% | $0 |
Consensus of the analysts covering Climb Bio, updated daily. In the last 30 days 3 estimates were raised and 2 lowered.
Frequently asked questions
What is the Climb Bio stock price target?
The average 12-month target from 15 analysts is $28.40, 174.1% above the current price of $10.36 Targets range from $18.00 to $40.00.
Is Climb Bio a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 14 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Climb Bio expected to earn?
Analysts expect EPS of $-0.75 for the fiscal year ending December 31, 2026 and $-0.99 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.